Skip to main content

Patients similar to yours say NovoSeven® RT fits into their lives.

Hear about the quick access to treatment and fast infusion of NovoSeven® RT, and how MixPro® and compact packaging fit in when traveling the world.

(Left to right): Taylor has CFVIId, and Justin and Bob have CHAwI.
 

Patients similar to yours say NovoSeven® RT fits into their lives.

  • Meet Justin

    In this video, Justin, who lives with hemophilia A with an inhibitor, talks about his love of travel, and how NovoSeven® RT fits in when he’s living life on the go. When he’s traveling internationally, the compact packaging of NovoSeven® RT is easy to take along.

  • Meet Bob

    In this video, you’ll hear from Bob about what it is like to live life with an inhibitor, and how important he finds the quick infusion time of NovoSeven® RT. Find out how NovoSeven® RT fits into his life.

  • Meet Chase

    Chase was diagnosed with hemophilia A as an infant and later developed an inhibitor. In this video, Chase and his grandmother discuss his favorite activities and how the quick infusion time and portability of NovoSeven® RT fit into their lives.

  • Meet Taylor

    Taylor, who lives with factor VII deficiency, loves to travel. Find out how the quick reconstitution of NovoSeven® RT fits in with the things she likes to do.

  • Meet Kali

    In this video, you'll hear from Kali about living with GT with refractoriness to platelets, and how she takes NovoSeven® RT along when she's on the go.

  • Meet Miguel

    In this video, you’ll hear from Miguel about living with hemophilia B with an inhibitor, and how the quick infusion time and compact packaging of NovoSeven® RT fits into his life.

Patient brochures

Help patients learn

about bleeding disorders.


NovoSecure™ website

Product support for

patients.


HCP educational brochures

Educational materials

for you.

Selected Important Safety Information

WARNING: THROMBOSIS

  • Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported
  • Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT
  • Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis

Warnings and Precautions

  • Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance
  • Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events

Indications and Usage

NovoSeven® RT (coagulation Factor VIIa, recombinant) is a coagulation factor indicated for:

  • Treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets
  • Treatment of bleeding episodes and perioperative management in adults with acquired hemophilia

Important Safety Information

WARNING: THROMBOSIS

  • Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported
  • Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT
  • Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis

Warnings and Precautions

  • Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance
  • Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events
  • Hypersensitivity reactions, including anaphylaxis, can occur with NovoSeven® RT. Patients with a known hypersensitivity to mouse, hamster, or bovine proteins may be at a higher risk of hypersensitivity reactions. Discontinue infusion and administer appropriate treatment when hypersensitivity reactions occur
  • Factor VII deficient patients should be monitored for prothrombin time (PT) and factor VII coagulant activity (FVII:C). If FVII:C fails to reach the expected level, or PT is not corrected, or bleeding is not controlled after treatment with the recommended doses, antibody formation may be suspected and analysis for antibodies should be performed
  • Laboratory coagulation parameters (PT/INR, aPTT, FVII:C) have shown no direct correlation to achieving hemostasis

Adverse Reactions

  • The most common and serious adverse reactions in clinical trials are thrombotic events. Thrombotic adverse reactions following the administration of NovoSeven® RT in clinical trials occurred in 4% of patients with acquired hemophilia and 0.2% of bleeding episodes in patients with congenital hemophilia

Drug Interactions

  • Thrombosis may occur if NovoSeven® RT is administered concomitantly with Coagulation Factor XIII

Please click here for Prescribing Information